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Abstract.
Background: A 57-year-old right-handed man was admitted to the Treviso Memory Clinic due to the presence of memory
forgetfulness, repetition of the same questions, episodes of confusion, initial difficulties in performing complex tasks and
easy distraction over the past two years, as well as recurrent and never-happened-before car accidents.
Objective: We report a peculiar case of an early onset Alzheimer’s disease (AD) with an unusual symptomatology, apparently
not fitting in any of the categorized atypical forms of AD nor being representative of a typical amnestic AD.
Methods: The patient underwent a neuropsychological, structural, and metabolic cerebral evaluation by MRI and 18F-FDG
PET, together with the search for cerebral amyloid (amyloid PET), a genetic testing for dementia related genes and the dosage
of CSF protein biomarkers of neurodegenerative conditions.
Results: We observed a convergence of predominant frontal (dysexecutive, verbal disinhibition) and posterior (visuospatial)
features of cognitive impairment. Structural MRI sequences showed subarachnoid spaces of the vault enlarged in the fronto-
parietal region with anterior and posterior cortical atrophy. The hippocampus appeared preserved. The 18F-FDG PET scans
showed hypometabolism in the prefrontal, lateral temporal, posterior parietal, and occipital regions bilaterally. The 18F-
Flutemetamol scan showed a diffused uptake of the amyloid tracer at the cerebral cortex. CSF biomarkers were compatible
with Alzheimer’s disease (AD).
Conclusion: This case report presented with clinical phenotypic aspects atypical of AD, both frontal and posterior, never
described as concomitant in the most accredited criteria for atypical AD, and appeared therefore more atypical than each of
the atypical AD phenotypes already reported.
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atrophy, TREDEM
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neuro-
degenerative condition usually developing in middle
to late life [1]. Its definition is two-fold, based on one
side on cluster of cognitive modifications and on the
other side on biomarkers and structural evidence of
AD pathology [2, 3].
In particular, the clinical profile of AD is gener-
ally characterized by an amnestic syndrome related
to hippocampal involvement with a specific episodic
memory deficit, whether isolated or associated with
other cognitive or behavioral symptoms [2]. Nonethe-
less, AD pathology can be present even in the absence
of clinical features, as shown by postmortem findings
of brain amyloidosis and tauopathy in asymptomatic
patients [3]. In the last decades, the neuropatho-
logy of AD has been detected in vivo at any stage of
the illness through amyloid- (A) positron emission
tomography (PET) imaging showing an augmented
concentration of A present in the brain, as well
as through cerebrospinal fluid (CSF) protein levels
evaluations which are related to the load of amy-
loid plaques, neurofibrillary tangles, and neuronal
degeneration [2–4]. These biological markers have
shown the highest specificity correlating with the
finding of AD pathology after death and represent
a fundamental milestone for the diagnosis of AD
during the patient’s life [4]. However, according to
estimates, 6 to 14% of AD patients possessing these
biological pathology features do not manifest the sort
of symptomatology above mentioned to be typical
of AD [4]. These cases are examples of “atypical
AD”, characterized by an earlier onset of the dis-
ease, a relatively preserved episodic memory and
a different clinical phenotype [2–4]. As stated by
the latest standards, atypical phenotypes include the
posterior variant—comprising an occipitotemporal
variant and a biparietal variant, the logopenic vari-
ant, and the frontal variant of AD [4]. Specifically, the
occipitotemporal posterior variant is defined by early,
prevalent, and progressive difficulties in visuoper-
ceptive functions or in visual recognition of objects,
symbols, words, or faces. Instead, in the biparietal
posterior variant the core impairment is in visu-
ospatial function, possibly with features of Balint
syndrome, Gerstmann syndrome, limb apraxia, or
neglect [4]. Diversely, the logopenic variant is dis-
tinguished by deficits in single word retrieval and
repetition of sentences. Finally, the frontal vari-
ant is characterized by behavioral changes such as
an increased manifestation of primary apathy or
disinhibition or predominant executive dysfunction
on cognitive testing [4].
Carrying out a differential diagnosis between the
different AD subtypes can be challenging, consider-
ing that no biomarker can distinguish typical from
atypical forms with consistent specificity [4]. Fur-
thermore, neither the conceptual theory underlying
atypical variants and their key features have been
described in depth, nor recommended tests for the
diagnosis have been operationalized [4, 5]. The issue
of the classification of the spectrum of atypical AD
can therefore be considered as unsettled and open
to changes [5]. For these reasons, the diagnostical
process of the clinical phenotype of AD relies to
date on the clinical history of the patient and on
the cognitive and behavioral symptoms, and employs
neuropsychological testing together with topograph-
ical biomarkers, such as cortical hypometabolism
in Fluorodeoxyglucose (18F-FDG) PET and corti-
cal atrophy in structural magnetic resonance imaging
(MRI), to support the identification of the clinical
variant [4].
The present work reports a peculiar case of an early
onset AD with an unusual symptomatology, appar-
ently not fitting in any of the categorized atypical
forms of AD while also not being representative of a
typical amnestic AD, thus presenting as of an “atyp-
ical” atypical AD phenotype.
Case presentation
In April 2019, a 57-year-old right-handed man was
admitted to the Treviso Memory Clinic due to the
presence of cognitive changes and forgetfulness over
the past two years, as well as recurrent and never-
happened-before car accidents which occurred from
October to December 2018. These events induced the
man, married and father of an adolescent, to close
the express courier business company he owned with
a friend, remaining unemployed for a month. After
starting to work again as an employee for another haul
company, his forgetfulness and difficulties in driving
the van persisted, to the extent of forcing him to take
a sick leave in January 2019.
No family history of neurodegenerative or psy-
chiatric diseases was reported, while other non-neu-
rological conditions of the patient included episodes
of asthma during the first years of life and alopecia for
the past 16 years. He also reported poor performance
at school, making frequent spelling mistakes in writ-
ing compositions and showing little interest in school
subjects. No sleep disturbances were reported. At the
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Fig. 1. CT scan (December 18, 2018), with no contrast, showing a modest enlargement of subarachnoid spaces of the vault with bilateral
parietal cortical atrophy and atrophy of posterior cortex especially in the higher sections. The hippocampus and the mesial temporal area
appear fairly preserved. Sagittal section not available.
Fig. 2. The first MRI study (January 12, 2019) is illustrated by the images above (a1-a5) while the second study (December 22, 2020)
produced the images below (b1-b5). (a1, a2, b1, b2 axial sections; a3, a4, b3, b4 coronal sections; a5, b5 sagittal sections). Not available
T1 sequences in the first study in the coronal and sagittal projections. Structural MRI T1 and T2 weighted sequences reported subarachnoid
spaces of the vault enlarged in the fronto-parietal region (b1, b2, a3, b3, a5, b5), anterior (b2, a5, b5) and posterior cortical atrophy especially
in the higher sections (a2, b2, a4, b4) and minimal gliotic alterations within the right-hemisphere’s white matter. The hippocampus and
the mesial temporal area appear fairly preserved (a3, b3). The comparison between the two studies shows an increase in frontal (b2) and
posterior (b2, b4) atrophy after 23 months.
time of the first visit, he used to smoke about four
cigarettes a day and reported no alcohol consumption.
He was not under any pharmacological treatment.
The onset of neurological symptoms dated back
to summer 2018, when the patient, aged 56, started
exhibiting forgetfulness, repetition of the same ques-
tions, episodes of confusion, initial difficulties in
performing complex tasks, and easy distraction.
In December 2018 the patient underwent a com-
puterized tomography (CT) scan, reporting a slight
enlargement of subarachnoid spaces of the vault
(Fig. 1).
In January 2019 the patient underwent a neurolog-
ical examination and was admitted to a Neurological
Clinic of a Hospital near his home, where he per-
formed a cerebral MRI, which showed enlarged
subarachnoid spaces of the vault and minimal gli-
otic alterations within the right-hemisphere’s white
matter (Fig. 2).
During the same hospital admission, he completed
a neuropsychological evaluation highlighting frontal
executive function deficits (Frontal Assessment Bat-
tery, FAB: 9/18 [6]; Phonemic Verbal Fluency:
25.4 [7]; Cognitive Estimation Test: 4/5 [7]; Clock
Drawing Test: 3/10 [7]), attention deficit (Attentive
Matrices: 20.25/60 [8]), severe visuospatial deficits
(Design Copy Test: 3.25/14 [8]), and memory impair-
ment (Short-Story Memory Test: 3/16 [8]).
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In January 2019, on the same hospital admission,
a diagnostic lumbar puncture was performed with
dosage of A1–42, tau, phospho-tau, and 14-3-3 pro-
teins.
Furthermore, in February of the same year he
underwent an electroencephalogram (EEG) which
revealed minimal signs of encephalic suffering, rep-
resented by inscription of theta sequences within
the alpha background rhythm. The patient was dis-
charged with the diagnosis of “Rapidly evolving
cognitive decline under investigation”. No treatment
followed the hospital discharge. In February 2019,
the patient underwent a 18F-FDG PET scan showing
a markedly reduced uptake in the parietal, lateral tem-
poral, and prefrontal regions bilaterally, greater in the
right hemisphere. The uptake was also reduced in the
precuneus especially on the right and less at the level
of the cingulate and in the occipital lobe.
The patient was referred to the Treviso Memory
Clinic in April 2019 for a second opinion. Upon
physical examination, he appeared a little anxious
with hasty speech. He had no focal neurological
deficits. Osteo-tendon reflexes were normal. No mus-
cle strength deficit was observed in any body district.
His walking was autonomous and normal. The patient
did not perform the index-nose tests correctly: he used
the thumb instead of the index finger and passed the
nose with both hands. Furthermore, he showed adi-
adochokinesia in the prone supination of the hands.
The patient was not affected by oculomotor apraxia,
nor simultanagnosia, nor optic ataxia. The language
was at times disinhibited.
At our first evaluation, the patient provided the
images of the CT study he had previously undergone.
A careful observation of the images showed not
only the enlargement of the subarachnoid spaces of
the vault but also a parietal and posterior cortical atro-
phy especially in the higher sections. The hippocam-
pus and the mesial temporal lobe appeared fairly
preserved (Fig. 1). Blood chemistry tests showed
only mild total hypercholesterolemia (222 mg/dl)
and the electrocardiogram was normal.
A neuropsychological evaluation was carried out
in April 2019 and showed deficits in memory, and
attention, constructional apraxia, ideomotor apraxia,
visual perception deficit, and executive dysfunctions
(Table 1). In a second clinical evaluation in May 2019,
it was possible to view images of the MRI study,
that showed also posterior cortical atrophy, and of the
18FDG PET exam that showed hypometabolism in the
parietal, temporal, and prefrontal regions bilaterally
and at the level of the precuneus and of the cingulate,
both previously performed at a different Hospital,
together with CSF evaluation which showed high lev-
els of tau protein, low ratio between A1–42 and p-tau
181 protein and the absence of 14-3-3 protein.
As early onset AD was suspected, an amyloid
Flutemetamol (18F) PET and a genetic testing for
dementia related genes (APP, PSEN1, and PSEN2)
were performed in June 2019.
The patient was placed on treatment with rivastig-
mine 4.6 mg/24 h transdermal patch and memantine
starting at 10 mg/daily and progressively titrated to
20 mg/daily.
A follow-up neuropsychological evaluation was
conducted in October 2019 and showed deficits
of memory, attention, and language, constructional
apraxia, ideomotor apraxia, visual perception deficit,
and executive dysfunction (Table 1). The patient was
evaluated periodically every 6 months. Due to an
overall cognitive worsening in December 2020, the
patient underwent a new 18FDG PET and brain MRI
scan at our hospital which showed an increase in
frontal and posterior cortical atrophy together with
an accentuation of hypometabolism in parietal, tem-
poral, prefrontal regions bilaterally as well as at the
level of the precuneus, cingulate, and occipital lobe.
The overall clinical history, the neuropsychologi-
cal and metabolic evidence, together with the amyloid
Flutemetamol (18F) PET and the pathological dosage
of biomarkers, oriented toward early onset AD with
the distinctive occurrence of both frontal and pos-
terior signs and symptoms seemingly pertaining to
different atypical AD variants.
MATERIALS AND METHODS
Neuropsychological evaluation
A neuropsychological evaluation was carried out
at admission in April 2019 and then in Octo-
ber 2019. Psychometric test results are included in
Table 1 (raw scores, corrected scores, and cut-offs).
The evaluation included the following tests: Clini-
cal Dementia Rating (CDR) [9], Mini-Mental State
Examination (MMSE) [10], Digit Span [11], Visuo-
Spatial Span [8], Short Story Memory Test [8],
Rey-Auditory Verbal Learning Test (RAVLT) [12],
Rey-Osterrieth Complex Figure Test (ROCF)-
detailed recall [13], Attentive Matrices [8], Semantic
and Phonemic Verbal Fluencies [8, 7], Token Test
[8], Design Copy Test [14], Rey-Osterrieth Com-
plex Figure Test (ROCF)-copy [13], Ideational
Apraxia [15], Ideomotor Apraxia [8], Tangled
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Table 1
Neuropsychological evaluations. The table shows the patient’s performance on tests of memory, attention, language, constructional apraxia,
ideomotor apraxia, visual perception, executive functions, and the comprehensive neuropsychiatric profile (raw scores, corrected scores, and
cut-off values are reported)
Neuropsychological test First evaluation Cut-Off Second evaluation Cognitive Domain
(April 2019) (October 2019)
Raw Corrected Raw Corrected
score score score score
Mini-Mental State Examination [7] 19 18.97 ≥23.80 18 17.97 General Cognitive Abilities
Clinical Dementia Rating [6] 1 N.A. 0.5 2 N.A.
RAVLT [9] RI = 26; RI = 26.7; RI > 28.53; RI = 22; RI = 22.7; Memory
RD = 0 RD = 0.2 RD > 4.69 RD = 0 RD = 0.2
Digit Span [8] 6 6 > 3.75 6 6
Visuo-Spatial Span [8] 2 1.75 (Z = –3.32) –1.5 < Z < 1.5 2 1.75 (Z = –3.32)
Short-Story Memory Test [8] 3 2.5 (Z = –2.65) –1.5 < Z < 1.5 3 2.5 (Z = –2.65)
ROCF – delayed recall [10] 0 –0.75 ≥9.47 0 –0.75
Attentive Matrices [13] 12 7.3 (Z = –4.89) –1.5 < Z < 1.5 11 6.5 (Z = –5) Attention
Phonemic Verbal Fluency Test [13] 24 26 ≥17.35 19 21 Language
Semantic Verbal Fluency Test [8] 8.5 7.5 ≥7.25 9.5 8.5
Token Test [8] 28 27.25 ≥26.5 19.5 18.75
Design Copy Test [13] 2 2.3 (Z = –4.95) –1.5 < Z < 1.5 2 2.3 (Z = –4.95) Constructional Praxia
ROCF – copy [10] 6.5 7 ≥28.88 3.5 4
Ideational Apraxia Test [15] 19/20 N.A. 20/20 N.A. Ideational Praxia
Ideomotor Apraxia Test [8] 19/20 N.A. 20/20 N.A. Ideomotor Praxia
Tangled Figures Test [11] 9 N.A. > 25 13 N.A. Visual Perception
Street’s Completion Test [8] 4/14 3 (Z = –2.27) –1.5 < Z < 1.5 4/14 3 (Z = –2.27)




Clock Drawing Test [11] 0/10 N.A. 0/10 N.A. Executive Functions
Cognitive Estimation Test [11] 5/5 N.A. 2/5 N.A.
Trail Making Test – A [18] N.E.∗ < 94 sec N.E.∗
Trail Making Test – B [18] N.E.∗ < 283 sec N.E.∗
Frontal Assessment Battery (FAB)
[19]
10/18 10.1 (Z = –8.12) –1.5 < Z < 1.5 10/18 10.1 (Z = –8.12)
Tower of London [20] N.E.∗ N.E.∗
NPI F X G [21] 4 N.A. 14 N.A. Neuropsychiatric Profile
N.A., not applicable; N.E., not executable; IR, immediate recall; DR, delayed recall; Scores outside the normal range are shown in bold.
The neuropsychological assessment showed a deficit in memory (RAVLT, Visuo-Spatial Span, Short Story Memory Test, ROCF-delayed
recall), attention (Attentive Matrices), constructional praxia (Design Copy Test, ROCF - copy), visual perception (Tangled Figures Test,
Street’s Completion Test), and executive functions (Clock Drawing Test, FAB). ∗This test was not concluded because the patient could not
understand the rule of the task. ∗∗This test was not executable because the patient showed a severe deficit in visual perception abilities.
Figures Test [7], Street’s Completion Test [8], Sil-
houettes Test [16], Poppelreuter-Ghent’s overlapping
figures test [17], Clock Drawing Test [7], Cognitive
Estimation Test [7], Trail Making Test (TMT) A and
B [18], Frontal Assessment Battery (FAB) [6], Tower
of London [19], and the Neuropsychiatric Inventory
(NPI) [20].
Structural and nuclear medicine imaging
The structural MRI scan was performed with 3-
T Magnetom 135 mT of gradients with 64 channels
(Siemens Magnetom Vida). T1, T2, and T2 FLAIR
weighted sequences were extracted.
The patient underwent a 18F-FDG PET brain scan
using a PET tomograph Discovery MI (General
Electric Healthcare). The CT scan was used for atten-
uation and scatter correction with set voltage tuned to
120 kV. The scan was obtained over 15 min, starting
60 min after i.v. injection of 227 MBq. The images of
the two scans were only visually assessed.
The patient also underwent a PET brain scan with
18F-Flutemetamol (Vizamil®), using a PET tomo-
graph Discovery MI (General Electric Healthcare).
The 18F-Flutemetamol study (Amyloid –  PET)
was obtained over 20 min starting 90 min after intra-
venous injection of 198 MBq. The images of the scan
were visually assessed.
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Cerebrospinal fluid analyses
CSF A1–42, total tau, and phosphorylated tau
levels were determined by using commercially avail-
able INNOTEST ELISA kit (Fujirebio Europe N.V.,
Ghent, Belgium), as previously described [21]. CSF
A1–42, tTau, and pTau181 levels were check in
duplicate. Pathological values were assumed for total
tau > 350 pg/mL and A1–42/pTau181 ratio < 7 [21].
The search for the 14-3-3 protein was also per-
formed by western blot technique [22].
Genetic analysis
To investigate the presence of mutations associ-
ated with AD, including APP, PSEN1, and PSEN2, a




The patient came to the clinical interviews accom-
panied by his wife. During the preliminary meeting
he reported the presence of recent memory problems,
difficulties in performing calculations, and difficul-
ties in concentration. The wife reported that the
patient frequently forgot his keys, his cell phone, and
other personal items, and that he was responsible for
several driving accidents. As a result, the patient, a
former van driver for his own haul company, had to
quit his job and was currently unemployed. During
the interview, the patient was alert and collabora-
tive, despite the presence of situational anxiety, easy
distractibility, and loss of attention, leading to impul-
sive and hasty responses. His attitude was not always
congruent with the context. He correctly recalled his
personal data and was partially oriented in space and
slightly disoriented in time. His spontaneous speech
was fluent. The level of his speech comprehension
was slightly impaired.
He exhibited apraxia during the execution of the
drawing tests (including the Clock drawing test). At
the Frontal Assessment Battery (FAB) there was a
considerable sensitivity to interference and a reduced
inhibitory control. There were major difficulties in
both oral and written calculation. His mood was
slightly low. It was not possible to administer the
entire neuropsychological assessment due to difficul-
ties in understanding the instructions necessary for
carrying out some of the tests.
The first cognitive testing session (April 2019)
highlighted a marked deficit in executive functions
(Clock Drawing Test [7], Frontal Assessment Bat-
tery [6], Trail Making Test (TMT) A and B [18],
Tower of London [19]). In addition, the patient’s
executive performance worsened and, at a second
evaluation (October 2019), a shortfall was evident in
the Cognitive Estimation Test [7], previously scored
within the normal range. The deficits in visual per-
ception were notable and proved stable between the
two evaluations (Tangled Figures Test [7], Street’s
Completion Test [8]). Moreover, significant impair-
ments were detected in the domains of memory
(RAVLT [12], Visuo-Spatial Span [8], Short-Story
Memory Test [8], ROCF – delayed recall [13]), atten-
tion (Attentive Matrices [8]) and of constructional
praxia (Design Copy Test [14], ROCF – copy [13]), in
which the patient scored below the normal threshold
and slightly worsened throughout the second evalua-
tion. A mild decline over the neuropsychiatric profile
between the first and the second neuropsychologi-
cal assessment was observed (NPI FxG [20]). Thus,
the two evaluations signaled an overall progressive
worsening of the clinical picture over six months.
Structural and nuclear medicine imaging
The CT scans (December 18, 2018) showed mod-
est atrophy of the vault with bilateral parietal and
posterior cortical atrophy especially in the higher sec-
tions. The hippocampus and the mesial temporal lobe
appeared fairly preserved (Fig. 1)
Structural MRI T1 and T2 weighted sequences
(January 12, 2019 and December 22, 2020), showed
subarachnoid spaces of the vault enlarged (Fig. 2: a3,
a4; b3, b4), posterior cortical atrophy especially in the
higher sections (a2, a4; b2, b4) and minimal gliotic
alterations within the right-hemisphere’s white mat-
ter. The hippocampus and the mesial temporal lobe
appeared fairly preserved (a3, b3), despite modest
motion artifacts. The comparison between the two
studies showed an increase in frontal and posterior
atrophy after 23 months.
The first (February 13, 2019) and the second
(December 22, 2020) 18F-FDG PET study showed
a marked reduction in radiopharmaceutical uptake in
the parietal (Fig. 3: a2-a4; b2-b4), lateral temporal
(a1; b1) and prefrontal regions bilaterally (a5, a6; b5,
b6), greater in the right hemisphere. The uptake was
also significantly reduced at the level of the precuneus
(a6; b6), especially on the right side, and slightly
impaired at the level of the cingulate (a6; b6) and of
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Fig. 3. The first 18F-FDG PET study (February 13, 2019) is illustrated by the images above (a1-a7) while the second study (December 22,
2020) produced the images below (b1-b7). (a1-a5, b1-b5 axial sections; a6, b6 sagittal sections; a7, b7 coronal sections). 18F-FDG PET
studies showed a marked reduction in radiopharmaceutical uptake in the parietal (a2-a4; b2-b4), lateral temporal (a1; b1) and prefrontal
regions bilaterally (a5, a6; b5, b6), greater in the right hemisphere. The uptake was also significantly reduced at the level of the precuneus
(a6; b6), especially on the right side, and slightly impaired at the level of the cingulate (a6; b6) and of the occipital lobe (a4, a5, a7; b4, b5,
b7). The comparison between the two studies shows a accentuation of hypometabolism in the same areas after about 22 months (b1-b8).
Fig. 4. Three-dimensional reconstruction with absorption ratio with respect to the Pons as reference region. Z score images to which a
threshold of 2 SD is applied. The red and yellow colors correspond to the areas with greater hypometabolism. The first 18F-FDG PET study
(February 13, 2019) is illustrated by the images above (a1-a8) while the second study (December 22, 2020) produced the images below
(b1-b8). (a1, b1 right side; a2, b2 left side; a3, b3 right medial; a4, b4 left medial; a5, b5 front; a6, b6 backside; a7, b7 upper; a8, b8 bottom).
The images clearly show that the bilateral temporoparietal hypometabolism was prevalent on the right (a1, b1) together with the involvement
of the precuneus (a3, b3). Some areas of the frontal (a5, b5) and of occipital cortex (a6, b6) are also clearly hypometabolic. The comparison
between the two studies shows a clear accentuation of hypometabolism in the same areas after about 22 months (b1-b8).
the occipital lobe (a4, a5, a7; b4, b5, b7). The com-
parison between the two studies showed an increased
hypometabolism in the same areas after about 22
months (b1-b8).
The 18F-FDG PET three-dimensional reconstruc-
tion (Fig. 4) clearly showed that the bilateral
temporoparietal hypometabolism was prevalent on
the right (a1, b1) together with the involvement of
the precuneus (a3, b3). Some areas of the frontal
(a5, b5) and of occipital cortex (a6, b6) were also
clearly hypometabolic. The comparison between the
two studies showed very clearly the hypometabolism
of both the posterior and the frontal cortex which was
accentuated after about 22 months (b1-b8).
The 18F-Flutemetamol scan showed a diffused
uptake of the amyloid tracer at the level of the cerebral
cortex, particularly in the frontal lobes, parietal lobes,
lateral temporal lobes, in the posterior cingulate,
bilaterally, and in correspondence of the striate nuclei
(Fig. 5).
Cerebrospinal fluid analysis
The CSF analysis revealed a A1–42 level of 305
ng/L, a t-tau protein dosage of 957 ng/L, a p-tau pro-
tein 181 dosage of 171 ng/L, while the ratio between
A1–42 and p-tau 181 protein was 1.8. 14-3-3 protein
in the CSF was not detected.
Genetic analysis
Mutations associated with AD (APP, PSEN1, and
PSEN2) were not found.
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Fig. 5. 18F-Flutemetamol PET scan highlighting a diffused uptake of the amyloid tracer at the level of the cerebral cortex, particularly in the
frontal lobes, parietal lobes, lateral temporal lobes, in the posterior cingulate, bilaterally and in correspondence of the striate nuclei.
DISCUSSION
From a neuropsychological perspective, our pa-
tient presented a very uncommon cluster of symp-
toms. Specifically, we observed a convergence of
predominant frontal (dysexecutive, verbal disinhibi-
tion) and posterior (visuospatial) features of cognitive
impairment, together with a memory loss and defi-
ciencies in the domains of language, attention and
constructional praxia. The severity of his clinical
symptomatology was substantial and disabling, espe-
cially considering his young age (57 years old at the
time of the first assessment in the Treviso Memory
Clinic) and home situation (the patient was married
and father of one kid). The loss of his job, due to the
clinical manifestation of the disease, represented an
additional aggravating factor, since the patient was
not able to provide economical support to his fam-
ily anymore. Moreover, the patient’s socialization
skills were undermined by his inability to maintain
sustained attention, combined with his sometimes
inappropriate and disinhibited behavior. Regarding
the cognitive testing sessions, the first neuropsycho-
logical evaluation (April 2019) highlighted a marked
deficit in executive functions that worsened (Cogni-
tive Estimation Test) after only six months, when
the second assessment was performed. The deficits
in visual perception were also conspicuous and sta-
ble between the two evaluations (Table 1). Other
impairments were detected in the domains of mem-
ory, attention, and constructional praxia, the latter
worsened by the second evaluation.
The patient while showing memory deficits typi-
cal of individuals with AD [2], markedly exhibited
evidence of an atypical AD clinical phenotype. Fur-
thermore, its atypical clinical features did not fulfil
current AD subtype classifications [4]. We are there-
fore facing a two-fold atypicality, since beyond
exhibiting symptoms that are representative of the
posterior variant of AD (such as early, prevalent and
progressive dysfunctions of visual-perceptive abili-
ties), our patient displayed impairments in the context
of executive functions and disinhibition, which are
characteristics of the frontal variant of AD [4].
Given the peculiar cluster of symptoms described
above, the patient presented with a variant of AD
more atypical than the previously reported atypi-
cal ones [4, 24]. In our clinical case, visuospatial
impairments, expression of posterior cortical dam-
age, appear to be the prevailing deficit also with
respect to compromised executive functions, man-
ifestation of frontal cortical damage. Visuospatial
disabilities strongly influenced the patient’s daily life
and could also be the main cause of his car accidents,
the reason that led the patient to consult a specialized
center for cognitive disorders.
The increasingly widespread use of biomarkers
has made it clear that the clinical presentation of
symptoms does not reliably indicate the underlying
neuropathology and that the same neuropathol-
ogy can manifest with different clinical phenotypes
[24, 25].
However, it is not yet clear why and how a certain
brain network rather than another becomes selec-
tively vulnerable to the onset of AD pathology [26].
Unlike beta amyloid protein, there would be a
close association between tau pathology and regional
neurodegeneration as well as clinical symptoms in
atypical forms of AD, including posterior cortical
atrophy [27], frontal behavioral variant of AD [28,
29], and primary progressive aphasia [30].
On the other hand, the lack in the clinical set-
ting of a PET ligand specific for neurofibrillary tau
pathology does not allow to verify the correspon-
dence between the topographical localization of tau
and the clinical phenotypic characteristics of AD
[24]. Although CSF tau measurements are a vali-
dated biomarker of tau neurofibrillary pathology [25],
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this biomarker does not allow to study the anatomical
localization of tau deposition.
We believe that, this case report has the merit of
exposing different clinical phenotypic aspects of AD,
both frontal and posterior in the same patient, not
described together in the most accredited criteria for
atypical AD [4]. A second strength is that the case
has been carefully studied from a clinical, structural,
metabolic, CSF and genetic point of view.
This case report also has some weaknesses.
A possible undiagnosed attention deficit at a young
age could explain both patient-reported poor school
performance and a more recent executive dysfunc-
tion.
Attention-deficit hyperactivity disorder (ADHD)
has historically been considered a disorder of child-
hood and adolescence. However, it is now recognized
that ADHD symptoms persist into adulthood in up to
60% of individuals [31]. The relationship between
ADHD and AD is a matter of debate. Some studies
have suggested an association between self-reported
specific learning disabilities in childhood and an
increased risk of atypical AD in adulthood and old
age [32, 33].
Other evidences, instead, suggest that ADHD is
a neurodevelopmental process fundamentally unre-
lated to mild cognitive impairment and dementia [31]
and it would appear to be a confounding rather than
a causal factor for dementia [34]. Future research is
needed to determine the underlying mechanisms that
predispose some, but not all people, with atypical
neurodevelopment, to develop atypical neurodegen-
erative disease.
A second weakness is that the patient was not com-
pletely cooperative during the MRI scan and some
sequences therefore showed modest motion artifacts.
Finally, the patient underwent the first instrumen-
tal examinations (CT, first MRI, first 18FDG PET) in
a different hospital; we therefore could not check the
quality of the first image examinations. We obtained
the first images via CD-rom and not via our Pic-
ture Archiving and Communication System (PACS)
[35]. The comparison of the same coronal and sagittal
MRI sections could only take place between different
sequences, T2 versus T1.
CONCLUSIONS
The case report derived from daily clinical prac-
tice, can offer an example of an undescribed clinical
presentation of atypical AD.
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